Neovacs S.A Год IPO
Что обозначает Год IPO в Neovacs S.A?
Год IPO Neovacs S.A. является 2010
Какое определение для Год IPO?
Первичное публичное размещение акций - это тип публичного предложения, при котором акции компании обычно продаются институциональным инвесторам, которые, в свою очередь, впервые продают эти акции широкой публике на фондовой бирже.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Год IPO компаний в Health Care сектор на EURONEXT по сравнению с Neovacs S.A
Что делает Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Компании с год ipo похож на Neovacs S.A
- Chigo имеет Год IPO из 2009
- Jade Road Investments имеет Год IPO из 2009
- Equity Metals имеет Год IPO из 2009
- Kerr Mines имеет Год IPO из 2009
- China e-Wallet Payment имеет Год IPO из 2009
- SQS India BFSI имеет Год IPO из 2009
- Neovacs S.A имеет Год IPO из 2010
- Broken Hill Prospecting имеет Год IPO из 2011
- Apollo Global Management Inc имеет Год IPO из 2011
- Hipo Resources имеет Год IPO из 2011
- Cogra 48 SA имеет Год IPO из 2011
- New Mountain Finance Corp имеет Год IPO из 2011
- Marfrig Global Foods SA имеет Год IPO из 2011